{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:28Z","timestamp":1787977048493,"version":"build-2784847793"},"reference-count":56,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8144-26","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:12:02Z","timestamp":1787609522000},"source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Guideline Perspectives on Methotrexate and Biologic\/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease"],"prefix":"10.2169","author":[{"given":"Hideaki","family":"Yamakawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Red Cross Hospital, Japan"},{"name":"Department of Respiratory Medicine, Tokyo Jikei University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yokosawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saitama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 376: 1094-1108, 2010.","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62: 1583-1591, 2010.","DOI":"10.1002\/art.27405"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev 30: 210011, 2021.","DOI":"10.1183\/16000617.0011-2021"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Koduri G, Solomon JJ. Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 75: 2067-2077, 2023.","DOI":"10.1002\/art.42640"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ito Y, Arinuma Y, Nakajima A. Evaluation and management of rheumatoid arthritis-associated interstitial lung disease. Respir Investig 63: 699-710, 2025.","DOI":"10.1016\/j.resinv.2025.05.011"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamakawa H, Ogura T, Kameda H, et al. Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). J Clin Med 10: 3806, 2021.","DOI":"10.3390\/jcm10173806"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kim JS, Pugashetti J, Ma SF, et al. Associations of interstitial lung disease subtype and CT pattern with lung function and survival. Thorax 80: 927-934, 2025.","DOI":"10.1136\/thorax-2024-222149"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamakawa H, Sato S, Tsumiyama E, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS\/ERS\/JRS\/ALAT criteria. J Thorac Dis 11: 5247-5257, 2019.","DOI":"10.21037\/jtd.2019.11.73"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mori S, Sakai F, Hasegawa M, Nakamura K, Sugahara K. Mortality and predictive factors for death following the diagnosis of interstitial lung disease in patients with rheumatoid arthritis: a retrospective, long-term follow-up study. J Clin Med 14: 1380, 2025.","DOI":"10.3390\/jcm14041380"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Venkat RK, Hayashi K, Juge PA, et al. Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 43: 2453-2466, 2024.","DOI":"10.1007\/s10067-024-07028-w"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. England BR, Yang Y, Roul P, et al. Heterogeneity of rheumatoid arthritis-associated interstitial lung disease by longitudinal forced vital capacity trajectory and associations with disease outcomes. Arthritis Care Res (Hoboken) 78: 249-258, 2026.","DOI":"10.1002\/acr.25620"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chang SH, Lee JS, Ha YJ, et al. Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 62: 3014-3024, 2023.","DOI":"10.1093\/rheumatology\/kead027"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sparks JA, He X, Huang J, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol 71: 1472-1482, 2019.","DOI":"10.1002\/art.40904"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chang SH, Paudel ML, McDermott GC, et al. Development of a prediction model for progression of rheumatoid arthritis-associated interstitial lung disease using serologic and clinical factors: the prospective KORAIL cohort. Semin Arthritis Rheum 73: 152729, 2025.","DOI":"10.1016\/j.semarthrit.2026.152912"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Brooks R, Baker JF, Yang Y, et al. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 61: 4667-4677, 2022.","DOI":"10.1093\/rheumatology\/keac208"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 47: 588-596, 2016.","DOI":"10.1183\/13993003.00357-2015"},{"key":"17","unstructured":"17. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology\/American College of Chest Physicians guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res (Hoboken) 76: 1051-1069, 2024."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Antoniou KM, Distler O, Gheorghiu AM, et al. ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Eur Respir J 67: 2402533, 2026.","DOI":"10.1183\/13993003.02533-2024"},{"key":"19","unstructured":"19. Alberti ML, Auteri SJ, Rojas-Serrano J, et al. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): an official 2025 ALAT clinical practice guideline. Arch Bronconeumol. Forthcoming."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Narvaez J, Diaz del Campo Fontecha P, Brito Garcia N, et al. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatol Clin 18: 501-512, 2022.","DOI":"10.1016\/j.reumae.2022.03.004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Crotti C, Ughi N, Scire CA, et al. The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease. Reumatismo 78, 2026.","DOI":"10.4081\/reumatismo.2025.1865"},{"key":"22","unstructured":"22. Kondoh Y, Bando M, Kawahito Y, et al. The guide for the diagnosis and treatment of connective tissue disease-associated interstitial lung disease 2025. Respir Investig 64: 101412, 2026."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fautrel B, Kedra J, Rempenault C, et al. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. Joint Bone Spine 91: 105790, 2024.","DOI":"10.1016\/j.jbspin.2024.105790"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yu KH, Chen HH, Cheng TT, et al. Consensus recommendations on managing selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore) 101: e28501, 2022.","DOI":"10.1097\/MD.0000000000028501"},{"key":"25","unstructured":"25. Singh S, Sharma BB, Bairwa M, et al. Management of interstitial lung diseases: a consensus statement of the Indian Chest Society and National College of Chest Physicians. Lung India 37: 359-378, 2020."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Oh JH, Lee JH, Chung SJ, et al. Korean guidelines for diagnosis and management of interstitial lung diseases: connective tissue disease associated interstitial lung disease. Tuberc Respir Dis (Seoul) 88: 247-263, 2025.","DOI":"10.4046\/trd.2024.0148"},{"key":"27","unstructured":"27. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology\/American College of Chest Physicians guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol 76: 1201-1213, 2024."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med (Lausanne) 6: 238, 2019.","DOI":"10.3389\/fmed.2019.00238"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dawson JK, Quah E, Earnshaw B, Amoasii C, Mudawi T, Spencer LG. Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol Int 41: 1055-1064, 2021.","DOI":"10.1007\/s00296-020-04773-4"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43: 613-626, 2014.","DOI":"10.1016\/j.semarthrit.2013.09.005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66: 803-812, 2014.","DOI":"10.1002\/art.38322"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Ann Intern Med 127: 356-364, 1997.","DOI":"10.7326\/0003-4819-127-5-199709010-00003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380: 752-762, 2019.","DOI":"10.1056\/NEJMoa1809798"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Sparks JA, Dellaripa PF, Glynn RJ, et al. Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled Cardiovascular Inflammation Reduction Trial. Arthritis Rheumatol 72: 2065-2071, 2020.","DOI":"10.1002\/art.41452"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhang Q, McDermott GC, Juge PA, et al. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 69: 152561, 2024.","DOI":"10.1016\/j.semarthrit.2024.152561"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 9: e028466, 2019.","DOI":"10.1136\/bmjopen-2018-028466"},{"key":"37","unstructured":"37. Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 57: 2000337, 2021."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ibfelt EH, Jacobsen RK, Kopp TI, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology (Oxford) 60: 346-352, 2021.","DOI":"10.1093\/rheumatology\/keaa327"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Park E, Iqbal R, Giles JT, Bernstein EJ. Use of methotrexate and TNF inhibitors in patients with rheumatoid arthritis-associated interstitial lung disease: a survey of rheumatologists. Clin Rheumatol 43: 3029-3032, 2024.","DOI":"10.1007\/s10067-024-07068-2"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Matson SM, Baqir M, Moua T, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest 163: 861-869, 2023.","DOI":"10.1016\/j.chest.2022.11.035"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Matson SM, Wang Y, McDermott GC, et al. Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax 80: 540-546, 2025.","DOI":"10.1136\/thorax-2024-222367"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Matteson EL, Aringer M, Burmester GR, Mueller H, Moros L, Kolb M. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol 42: 2311-2319, 2023.","DOI":"10.1007\/s10067-023-06623-7"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381: 1718-1727, 2019.","DOI":"10.1056\/NEJMoa1908681"},{"key":"44","unstructured":"44. Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 11: 87-96, 2023."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Atienza-Mateo B, Serrano-Combarro A, Loarce Martos J, et al. Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients. Semin Arthritis Rheum 72: 152710, 2025.","DOI":"10.2139\/ssrn.5092795"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Mena-Vazquez N, Rojas-Gimenez M, Godoy-Navarrete FJ, et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease. Biomedicines 10: 1480, 2022.","DOI":"10.3390\/biomedicines10071480"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Atienza-Mateo B, Fernandez-Diaz C, Loarce-Martos J, et al. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis. Eur J Intern Med 119: 118-124, 2024.","DOI":"10.1016\/j.ejim.2023.08.025"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor agents: a retrospective cohort study. Arthritis Res Ther 17: 319, 2015.","DOI":"10.1186\/s13075-015-0835-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. McDermott GC, Solomon DH, Sparks JA, Desai RJ. Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum 78: 152973, 2026.","DOI":"10.1016\/j.semarthrit.2026.152973"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Frideres H, Wichman CS, Dong J, et al. Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: a propensity score-matched, active-comparator, new-user study. Semin Arthritis Rheum 73: 152735, 2025.","DOI":"10.1016\/j.semarthrit.2025.152735"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. England BR, Baker JF, George MD, et al. Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study. Lancet Rheumatol 7: e166-e177, 2025.","DOI":"10.1016\/S2665-9913(24)00265-0"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Wu Z, Shih PC, Wang SI, et al. Comparative effectiveness of tocilizumab versus rituximab in rheumatoid arthritis-associated interstitial lung disease: an emulated target trial. Chest 169: 428-439, 2026.","DOI":"10.1016\/j.chest.2025.09.009"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Narvaez J, Aguilar-Coll M, Roig-Kim M, et al. Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 23: 103636, 2024.","DOI":"10.1016\/j.autrev.2024.103636"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Tsujimoto K, Ebina K, Okamura S, et al. Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort. Rheumatology (Oxford) 64: 4207-4217, 2025.","DOI":"10.1093\/rheumatology\/keaf157"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Lee KA, Lee B, Kim HS. Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD. Semin Arthritis Rheum 77: 152921, 2026.","DOI":"10.1016\/j.semarthrit.2026.152921"},{"key":"56","unstructured":"56. Solomon JJ, Dieud\u00e9 P, Matson SM, et al. Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement. Lancet Respir Med. Forthcoming."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8144-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:31:59Z","timestamp":1787974319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8144-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":56,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8144-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8144-26"}}